Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine

11723,589

16/578002

September 20, 2019

The present invention generally relates to compositions comprising anesthesia-reversing agents which facilitate or increase the time of awakening or reverse the effects of general anesthesia-induced unconsciousness. In some embodiments, the anesthesia reversing agent can be selected from any or a combination of methylphenidate (MPH), amphetamine, modafinil, amantadine, caffeine, or analogues or derivatives thereof. In some embodiments, compositions comprising at least one or more anesthesia-reversing agents can be used to facilitate awakening from anesthesia without or decreasing occurrence of delirium, and can be used in methods to treat or prevent the symptoms associated with emergence delirium, as well as treat a subject oversedated with general anesthesia. The invention also relates to methods for administering these compositions comprising anesthesia-reversing agents to subjects and for use.

The General Hospital Corporation (Boston, MA, US)

The General Hospital Corporation (Boston, MA, US)

1. A method of facilitating emergence from general anesthesia in a subject treated with a general anesthetic agent comprising sevoflurane or propofol, the method comprising administering to the subject an effective amount of a composition comprising dextro-amphetamine, wherein the dextro-amphetamine facilitates emergence of the subject from the general anesthesia.

2. The method of claim 1 , wherein emergence of the subject from general anesthesia comprises restoration of mobility or consciousness in the subject.

3. The method of claim 1 , wherein the dextro-amphetamine is administered by intravenous dose.

4. The method of claim 1 , wherein the subject is a perioperative anesthetized patient.

5. The method of claim 1 , wherein the subject is no longer being administered the general anesthesia agent.

6. The method of claim 1 , wherein the subject is administered the composition comprising dextro-amphetamine immediately prior to cessation of administration of the general anesthesia agent.

7. The method of claim 1 , wherein the subject is administered the composition comprising dextro-amphetamine immediately subsequent to cessation of administration of the general anesthesia agent.

8. The method of claim 3 , wherein the administration of a composition comprising dextro-amphetamine is via continuous administration.

9. The method of claim 3 , wherein the administration of a composition comprising dextro-amphetamine is via pulse administration.

2507631 May 1950 Panizzon
2957880 October 1960 Rudolf
4522811 June 1985 Eppstein et al.
5192527 March 1993 Abrahmsohn
5908850 June 1999 Zeitlin et al.
6025362 February 2000 Fukunaga et al.
6281242 August 2001 Regan et al.
6872390 March 2005 Weber et al.
7164025 January 2007 Langston et al.
20040143021 July 2004 Larijani
20070123468 May 2007 Jenkins
20090076023 March 2009 Weber et al.
20090131338 May 2009 Satou et al.
20110021564 January 2011 Sanfilippo
20110262442 October 2011 Hamilton et al.
20150196249 July 2015 Brown et al.
20160022659 January 2016 Winston
20220062206 March 2022 Solt et al.
WO-0059479 October 2000
WO 2012/031125 March 2012

Michel et al. (“Acute amphetamine abuse Problems during general anaesthesia for neurosurgery.” anaesthesia, 1979, vol. 34, pp. 1016-1101 9 (Year: 1979). cited by examiner
Extended European Search Report in European Appln. No. 19899707.4, dated Aug. 10, 2022, 9 pages. cited by applicant
International Preliminary Report on Patentability in International Appln. No. PCT/US2019/067591, dated Jul. 1, 2021, 9 pages. cited by applicant
International Search Report and Written Opinion in International Appln. No. PCT/US2019/067591, dated Feb. 28, 2020, 17 pages. cited by applicant
Jasinski and Krishnan, “Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers,” Journal of Pharmacology, 2009, 23(4):410-418. cited by applicant
Naaz and Ozair, “Dexmedetomidine in Current Anaesthesia Practice—a Review,” J Clin Diagn Res., Oct. 2014, 8(10):GE01-GE04. cited by applicant
Nelson et al., “The α2-Adrenoceptor Agonist Dexmedetomidine Converges on an Endogenous Sleep-promoting Pathway to Exert Its Sedative Effects,” Anesthesiology, Feb. 2003, 98(2):428-436. cited by applicant
Scheinin et al., “Reversal of the sedative and sympatholytic effects of Dexmedetomidine with a specific [alpha]2-Adrenoceptor antagonist atipamezole: a pharmacodynamic and kinetic study in healthy volunteers,” Anesthesiology, Sep. 1998, 89:574-584. cited by applicant
Alkire et al., “Thalamic Microinjection of Nicotine Reverses Sevoflurane-induced Loss of Righting Reflex in the Rat,” Anesthesiology, Aug. 2007, 107:264-272. cited by applicant
Alkire et al., “Consciousness and Anesthesia,” Science, Nov. 2008, 322: 876-880. cited by applicant
Antognini et al., “Propofol, more than halothane, depresses electroencephalographic activation resulting from electrical stimulation in reticular formation,” Acta Anaesthesiol Scand, 2006, 50(8):993-998. cited by applicant
Chemali et al., “Active Emergence from Propofol General Anesthesia Is Induced by Methylphenidate,” Anesthesiology, May 2012, 116: 998-1005. cited by applicant
Chemali et al., “Methylphenidate actively induces emergence from propofol general anesthesia,” Presentation Abstract, Neuroscience, 2011, 2 pages. cited by applicant
Chidambaran et al, “Evaluation of propofol anesthesia in morbidly obese children and adolescents,” BMC Anesthesiology, 2013, 13: 8 (9 pages). cited by applicant
Ching et al., “Thalamocortical model for a propofol-induced α-rhythm associated with loss of consciousness,” PNAS, Dec. 2010, 107(52):22665-22670. cited by applicant
Diaz and Kaye, “Death by Propofol,” J La State Med Soc, 2017, 169: 28-32. cited by applicant
Dodson et al., “Postoperative Effects of Methylphenidate,” British Journal of Anaesthesia, 1980, 52(12):1265-1270. cited by applicant
Eckenhoff, “Promiscuous Ligand and Attractive Cavities: How do the inhaled anesthetics work?,” Molecular Interventions, Dec. 2001, 1(5): 258-268. cited by applicant
Eger II, “Age, Minimum Alveolar Anesthetic Concentration, and Minimum Alveolar Anesthetic Concentration-Awake,” Anesth Analg, 2001, 93(4): 947-53. cited by applicant
European Patent Office Extended European Search Report, Application No. 12781958.9, dated Sep. 15, 2014, 12 pages. cited by applicant
Fasting and Gisvold, “Serious intraoperative problems—a five-year review of 83,844 anesthetics,” Can J Anesth, 2002, 49: 545-553. cited by applicant
Ferguson et al. (“Methylphenidate (Ritalin) hydrochloride parenteral solution: preliminary report.” Journal of the American Medical Association 162.14 (1956): Abstract). cited by applicant
Franks, “General anaesthesia: from molecular targets to neuronal pathways of sleep and arousal,” Nat. Rev. Neurosci., 2008, 9:370-386. cited by applicant
Grasshoff et al., “Molecular and systemic mechanisms of general anaesthesia: the ‘multi-site and multiple mechanisms’ concept,” Current Opinion in Anaesthesiology, 2005, 18:386-391. cited by applicant
Hahn et al., “A Direct Dynamic Dose-Response Model of Propofol for Individualized Anesthesia Care,” Journal of Late, Class Files, 2007, 6(1):1-8. cited by applicant
Han et al., “Deaths from recreational use of propofol in Korea,” Forensic Science International, 2013, 233: 333-337. cited by applicant
Heal et al., “The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety,” Neuropharmacology, Dec. 2009, 57:608-18. cited by applicant
Homer et al., “Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex,” Eur. J. PharmacoL, Mar. 2007, 558:96-97. cited by applicant
Hudetz et al., “Cholinergic reversal of isoflurane anesthesia in rats as measured by cross-approximate entropy of the electroencephalogram,” Anesthesiology, 2003, 99:1125-1131. cited by applicant
John, et al., Invariant Reversible QEEG Effects of Anesthetics, Consciousness and Cognition, 2001, 10:165-183. cited by applicant
Jurd et al., “General anesthetic actions in vivo strongly attenuated by a point mutation in the GABAA receptor B3 subunit,” FASEB J, 2003, 17(2):250-2. cited by applicant
Katsuga et al, “General anesthesia for two patients taking methylphenidate (Ritalin),” Masui, 2008, 57:748-751 (with English abstract). cited by applicant
Kelz et al., “An essential role for orexins in emergence from general anesthesia,” PNAS, 2008, 105:1309-1314. cited by applicant
Kenny et al, “Dextroamphetamine (but Not Atomoxetine) Induces Reanimation from General Anesthesia: Implications for the Roles of Dopamine and Norepinephrine in Active Emergence,” PLoS One, Jul. 2015, 10(7):e0131914, 16 pages. cited by applicant
Klausz et al, “Evaluation of a fatal propofol intoxication due to self administration,” Journal of Forensic and Legal Medicine, 2009, 16: 287-289. cited by applicant
Kranioti et al, Lethal self administration of propofol (Diprivan) a case report and review of the literature, Forensic Science International, 2007, 167: 56-58. cited by applicant
Letter from the Department of Health & Human Services—Food and Drug Administration, dated Aug. 11, 2010, 12 pages. cited by applicant
Liley et al., Propofol and Remifentanil Differentially Modulate Frontal Electroencephalographic Activity, Anesthesiology, 2010, 113:292-304. cited by applicant
Luo et al., “Basal forebrain histaminergic transmission modulates electroencephalographic activity and emergence from isoflurane anesthesia,” Anesthesiology, 2009, 111:725-733. cited by applicant
Maier et al., “Todesfalle durch Propofolmissbrauch. Befragung in rechtsmedizinischen Instituten in Deutschland, Osterreich und der Schweiz,” Anaesthesist, 2017, 66: 109-114 (with English abstract—p. 111). cited by applicant
Monroe et al, “The Misuse and Abuse of Propofol,” Substance Abuse & Misuse, 2011, 46: 1199-1205. cited by applicant
Purdon et al., “Simultaneous Electroencephalography and Functional Magnetic Resonance Imaging of General Anesthesia,” Ann. N.Y. Aced. Sci., 2009, 1157:61-70. cited by applicant
Ririe et al., “Unexpected interaction of methylphenidate (Ritalin) with anaesthetic agents,” Paediatr. Anaesth., 1997, 7:69-72. cited by applicant
Saper et al., “Hypothalamic regulation of sleep and circadian rhythms,” Nature, Oct. 2005, 437:1257-1263. cited by applicant
Saraghi et al, “Propofol: an Overview of Its Risks and Benefits,” Compendium, Apr. 2013, 34:252-258. cited by applicant
Solt and Forman, “Correlating the clinical actions and molecular mechanisms of general anesthetics,” Curr Opin Anaesthesiol, 2007, 20:300-306. cited by applicant
Solt et al., “Methylphenidate, but not physostigmine, restores righting in rats during isoflurane hypnosis,” Proceedings of the 2010 Annual Meeting of the American Society Anesthesiologists, Oct. 2010, 2 pages. cited by applicant
Taylor et al, “Activation of DI dopamine receptors restores the righting reflex during continuous isoflurane anesthesia,” Presentation Abstract, Neuroscience, Nov. 2011, 2 pages. cited by applicant
Vuyk et al. “Chapter 30: Intravenous Anesthetics.” Anesthesia, 2015, 822-832. cited by applicant
Wilson et al., “The abuse potential of propofol,” Clinical Toxicology, 2010, 48: 165-170. cited by applicant
Kato et al., “D-Amphetamine Rapidly Reverses Dexmedetomidine-Induced Unconsciousness in Rats,” Front Pharmacol., May 18, 2021, 12:668285, 10 pages. cited by applicant
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2011/050213, dated Mar. 5, 2013, 7 pages. cited by applicant
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2011/050213, dated May 1, 2012, 10 pages. cited by applicant

edspgr.11723589